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NCL

:   neuronal ceroid lipofuscinosis

PPT1

:   palmitoyl protein thioesterase 1

A 10‐month‐old, 29 kg (63 lb), spayed female Cane Corso dog was referred to the University of Wisconsin, School of Veterinary Medicine, with a 2‐month history of progressive blindness, ataxia, and lethargy. The dog was acquired by a family from a breeder at 8 weeks of age and was the only dog in the household. Both parents of the dog were healthy at the time this case presented. We were unable to obtain information on the health status of any littermates. Approximately 2 months prior to presentation, the dog had difficulty navigating in low light. Over the next 2 months, the visual impairment progressed to apparent blindness. Progressive ataxia was noted starting approximately 1 month prior to presentation, prompting referral.

On initial evaluation at the University of Wisconsin, the dog\'s physical examination was within normal limits. Abnormalities identified during a complete neurologic examination included a mild right head tilt, a positional right ventral strabismus, an absent menace response bilaterally with intact pupillary light reflexes elicited by bright light stimuli, an absent paw replacement test of the left pelvic limb, and a moderate vestibular ataxia with truncal sway and hypermetria of all limbs. The neuroanatomic lesion localization was considered multifocal, most apparent in the prosencephalon and cerebellum. The preliminary differential diagnoses were meningoencephalitis, hydrocephalus, abiotrophy, neoplasia, or lysosomal storage disorder. Because a disease with similar signs had not been previously described in this breed, a de novo mutation was considered a possible cause.

The recommended diagnostic tests included a complete blood count, blood chemistry, urinalysis, urine metabolic screen for inborn errors of metabolism, infectious disease testing, thoracic radiographs, brain magnetic resonance imaging, and cerebrospinal fluid analysis. All testing was declined except the urine metabolic test and infectious disease testing. Serum distemper by RT‐PCR, serum *Neospora caninum* by IFA, the *Cryptococcus neoformans* antigen test, and *Blastomycosis* urine antigen were all negative. The urine metabolic screen[1](#jvim14632-note-1003){ref-type="fn"} showed a slightly positive mucopolysaccharidosis spot test, which was attributed to young age, and glutamine and taurine levels were slightly above the reference range. The dog was discharged with instructions to administer prednisone (0.5 mg/kg per os q12h). Because the neurologic condition continued to deteriorate, euthanasia was elected 5 days after discharge.

A complete necropsy was performed. Abnormal findings were limited to the central nervous system. The brain was bilaterally symmetric and the cerebellar size was proportionate to the cerebrum, with no evidence of cerebellar herniation or ventricular dilatation. Histologic abnormalities were found in the cerebrum and cerebellum. In the cerebrum, there was marked gliosis throughout white matter tracts, most prominently in the corpus callosum. The affected dog exhibited a dramatically lower cell density in the external granular layer of the cerebral cortex compared to an age‐matched normal Beagle (Fig [1](#jvim14632-fig-0001){ref-type="fig"}A,B). In the affected dog, this brain layer also exhibited pronounced GFAP labeling of the astrocytes that was not observed in the brain from the normal dog (Fig [1](#jvim14632-fig-0001){ref-type="fig"}C,D). Substantial disease‐related GFAP immunostaining was also observed in the cerebral cortical white matter tracts of the affected dog. Cerebral cortical neurons of the affected dog also contained large aggregates of PAS‐positive material in the perinuclear cell bodies (Fig [2](#jvim14632-fig-0002){ref-type="fig"}). The granular layer of the cerebellum was markedly hypocellular, and marked astrogliosis was noted throughout all layers of the cerebellar cortex and in the arbor vitae white matter as indicated by immunohistochemical staining for GFAP (Fig [3](#jvim14632-fig-0003){ref-type="fig"}). The retinas were not adequately prepared to evaluate for truncation of the photoreceptor outer segments as reported in a human case of palmitoyl protein thioesterase 1 (PPT1) deficiency,[1](#jvim14632-bib-0001){ref-type="ref"} but dark‐staining inclusions could be seen surrounding the nuclei in some retinal cells.

![Light micrographs of paraffin sections of the cerebral cortex external granular layer from the neuronal ceroid lipofuscinosis‐affected Cane Corso (**A** and **C**) and from an age‐matched normal Beagle (**B** and **D**). A and B were stained with hematoxylin and eosin. C and D were immunostained with an anti‐GFAP antibody. The diseased dog exhibited a substantial reduction in cell density in the external granular layer and substantial numbers of GFAP‐labeled astrocytes that were not observed in the control dog sample. Bar in (D) indicates magnification of all micrographs.](JVIM-31-149-g001){#jvim14632-fig-0001}

![Light micrographs of diastase‐treated PAS‐stained section of the cerebral cortex from the affected dog. Aggregates of PAS‐staining inclusions were present in the perinuclear areas of most cortical neurons (arrows).](JVIM-31-149-g002){#jvim14632-fig-0002}

![GFAP immunohistochemical stained sections of the cerebellum from the affected Cane Corso (**A** and **C**) and from a normal Beagle of similar age (**B** and **D**). Images (A) and (B) show regions of the cerebellar cortex and images (C) and (D) show regions of the arbor vitae at the bases of the folia. In the affected dog, cells showing pronounced GFAP immunostaining were present in all layers of the cortex (m: molecular layer, p: Purkinje cell layer; g: granular cell layer) (A) as well as in the arbor vitae (B). No cells exhibited substantial GFAP immunostaining in either the cerebellar cortex or arbor vitae of the normal dog (B and D). Note also the sparsity of cell nuclei in the granular cell layer of the affected dog (A) compared to the normal dog (B).](JVIM-31-149-g003){#jvim14632-fig-0003}

Based on the clinical and histologic findings, neuronal ceroid lipofuscinosis (NCL) was suspected. Thus, paraffin blocks, formalin‐fixed tissues, and EDTA‐anticoagulated blood were shipped to the University of Missouri for further analysis. The NCLs are lysosomal storage diseases in which autofluorescent storage inclusions with distinct ultrastructure accumulate in the cytoplasm of neurons and other cell types. The NCLs are almost always recessively inherited and affected individuals experience progressive neurodegeneration and premature death.[2](#jvim14632-bib-0002){ref-type="ref"}

Previously described fluorescent microscopic procedures[3](#jvim14632-bib-0003){ref-type="ref"} were used to examine the tissues from the affected Cane Corso. Massive accumulations of autofluorescent storage material were present throughout the brain and the retina (Fig [4](#jvim14632-fig-0004){ref-type="fig"}). In the cerebral cortex and midbrain, almost all of the neurons contained large amounts of this material concentrated primarily in the perinuclear areas of the cells (Fig [4](#jvim14632-fig-0004){ref-type="fig"}A,B). In the cerebellar cortex, the storage material was present in the Purkinje cells and in large masses in the granular cell layer (Fig [4](#jvim14632-fig-0004){ref-type="fig"}C). Large amounts of the autofluorescent storage material were also present in the perinuclear regions of neurons in the deep cerebellar nuclei (Fig [4](#jvim14632-fig-0004){ref-type="fig"}D). In the retina, the storage material was concentrated primarily in the ganglion cells, although small amounts of the autofluorescent material were scattered throughout the retina with a relatively large amount forming a continuous layer along the outer limiting membrane (Fig [4](#jvim14632-fig-0004){ref-type="fig"}E).

![Fluorescence micrographs of unstained sections of (**A**) cerebellar cortex, (**B**) cerebral cortex, (**C**) retina, (**D**) deep cerebellar nucleus, and (**E**) retina. In (A), arrows point to Purkinje cells; m: molecular layer, p: Purkinje cell layer, g: granular cell layer. In (C), arrows point to Purkinje cell bodies. In (E), arrows point to retinal ganglion cells and arrow heads point to the outer limiting membrane; g: ganglion cell layer, ipl: inner plexiform layer, inl: inner nuclear layer, onl: outer nuclear layer. Bar in (A) indicates magnification of all micrographs.](JVIM-31-149-g004){#jvim14632-fig-0004}

Small pieces of formalin‐fixed cerebellar and cerebral cortex and retina were washed in sodium cacodylate buffer and then incubated in cacodylate‐buffered 2.5% glutaraldehyde before being processed for electron microscopic examination. In the Purkinje cells, cerebral cortical neurons, and retinal ganglion cells, the storage body contents appeared to consist primarily of aggregates of membrane‐like structures. In the Purkinje cells, these structures were similar in appearance to mitochondrial cristae (Fig [5](#jvim14632-fig-0005){ref-type="fig"}A), whereas, in the other cell types, the material was much more condensed with the membrane‐like profiles tightly packed together (Fig [5](#jvim14632-fig-0005){ref-type="fig"}B,C). Although the aggregated material formed distinct structures in all 3 tissues, membranes enclosing these aggregates were not observed except in the case of some Purkinje cell inclusions, most likely because such membranes are not well preserved with formalin fixation.

![Electron micrographs of the disease‐specific storage bodies from a cerebellar Purkinje cells (**A**), a cerebral cortical neuron (**B**), and a retinal ganglion cell (**C**).](JVIM-31-149-g005){#jvim14632-fig-0005}

In conjunction with the clinical signs, the light and electron microscopic results indicated the dog had NCL. To identify the molecular genetic cause of this Cane Corso\'s disease, we used the dog\'s DNA to generate a whole genome sequence. This has proven to be an efficient strategy for identifying the mutations responsible for NCL.[3](#jvim14632-bib-0003){ref-type="ref"}, [4](#jvim14632-bib-0004){ref-type="ref"}, [5](#jvim14632-bib-0005){ref-type="ref"}, [6](#jvim14632-bib-0006){ref-type="ref"}, [7](#jvim14632-bib-0007){ref-type="ref"} Procedures for DNA isolation, library preparation, sequence generation, and sequence analysis are provided in the Data S1. The affected Cane Corso\'s whole genome sequence had 29‐fold average coverage and contained 10,965 variants predicted to alter the primary structure of the encoded proteins. Only 4 of these variants occurred within 1 of the 13 genes (*PPT1*,*TPP1*,*CLN3*,*CLN5*,*CLN6*,*MFSD8, CLN8, CTSD, DNAJC5, CTSF, ATP13A2, GRN,* and *KCTD7*)[8](#jvim14632-bib-0008){ref-type="ref"} associated with human NCL. Three of these variants were heterozygous missense mutations in *ATP13A2* (Table [1](#jvim14632-tbl-0001){ref-type="table-wrap"}) and all 3 had previously been reported in the SNPdb database. The nonreference allele frequencies for these variants in 45 control whole genome sequences from normal dogs or dogs with other diseases approached or exceeded 50% and the nonreference allele was homozygous in from 15 to 19 of these control whole genome sequences (Table [1](#jvim14632-tbl-0001){ref-type="table-wrap"}). These common sequence variants that were heterozygous in the affected dog are therefore very unlikely to have contributed to the dog\'s rare recessive disease.

###### 

Sequence variants in neuronal ceroid lipofuscinosis‐associated genes

  Chromosomal Coordinate[a](#jvim14632-note-0005){ref-type="fn"}   Zygosity       cDNA Change            Amino Acid Change   SNPdb Reference   Frequency in Controls
  ---------------------------------------------------------------- -------------- ---------------------- ------------------- ----------------- -----------------------
  g.81203298 (CFA2)                                                Heterozygous   *ATP13A2:c.251A\>G*    p.H84R              rs852341627       0.485
  g.81204154 (CFA2)                                                Heterozygous   *ATP13A2:c.81204154*   p.M164T             rs851078079       0.542
  g.81215472 (CFA2)                                                Heterozygous   *ATP13A2:c.3469A\>G*   p.M1157V            rs850751821       0.622
  g.2860424 (CFA15)                                                Homozygous     *PPT1:c.124 + 1G\>A*   Splice variant      None              Zero

CanFam3.1 genome assembly.
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The remaining variant, a *PPT1c.124 + 1G\>A* splice donor mutation, is much more likely to be the cause of the NCL in this case. The nonreference allele was homozygous in the affected dog, has not previously been reported in dbSNP, and was absent from the whole genome sequences of 45 control dogs. The Integrative Genomics Viewer genome browser (<https://www.broadinstitute.org/igv/>) was used to visualize the variant (Fig [6](#jvim14632-fig-0006){ref-type="fig"}) and its validity was independently verified by Sanger sequencing (details in Data S1). The *PPT1c.124 + 1G\>A* mutation destroys the splice donor consensus motif required for exon recognition and exon‐to‐exon splicing by the spliceosome.[9](#jvim14632-bib-0009){ref-type="ref"} Mutations in the "*G*" of the canonical "*GT*" or "*GC*" motifs found immediately 3′ to all but the last exon in mammalian genes are the most common category of disease‐causing splice site mutations.[10](#jvim14632-bib-0010){ref-type="ref"} Mutations that weaken or destroy splice donor sites can alter exon splicing patterns in 3 ways. They can result in the skipping of the adjacent exon, the use of nearby cryptic splice sites, or the inclusion of the intron.[11](#jvim14632-bib-0011){ref-type="ref"} The splice donor mutation in the Cane Corso with NCL cannot induce exon skipping because it occurs adjacent to exon 1 which also contains the initiator methionine codon. A scan of the genomic DNA sequence for potential nearby cryptic sites identified 3 "*GT*" motifs within 50 bp of the splice donor mutation: 2 in exon 1 with starting positions at −48 and −19 relative to the intron/exon junction and 1 in intron 1 starting at position +19 relative to the intron/exon junction. However, an internet tool (<http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html>) that estimates the strength of splice donor signals based on maximum entropy modeling of the nucleotide sequences that surround the canonical "*GT*" motifs[12](#jvim14632-bib-0012){ref-type="ref"} indicated that none of the 3 "*GT*" motifs near the splice donor mutation reside in potential cryptic splice sites (Table [2](#jvim14632-tbl-0002){ref-type="table-wrap"}). Thus, transcripts from *PPT1* with the splice donor mutation are most likely to retain the 5′ end of the 4.6 kb intron 1. If these transcripts escaped nonsense‐mediated decay[13](#jvim14632-bib-0013){ref-type="ref"} and were translated, they would be expected to produce a severely truncated gene product containing 42 amino acids at the N‐terminal end encoded by exon 1 followed by 114 unrelated amino acids encoded by intron 1 before the first in‐frame termination codon. Nonetheless, it is highly unlikely that the mutant *PPT1* could produce a product that retained any biologic function.

![A screen capture of the affected Cane Corso\'s whole genome sequence alignment over 42 bp of canine chromosome 15 visualized with the Integrative Genomics Viewer. Each gray bar represents sequence reads aligned to the CanFam3.1 reference sequence assembly shown with the 4‐color nucleotide sequence near the bottom of the figure. Variants in the sequence reads are indicated by letters at the pertinent positions within the gray bars. In this case, the As within the gray bars indicate the variant\'s position where an ***A*** in a sequence read replaces a ***G*** from the reference sequence. Colors were modified from the screen capture to enhance visibility of the As. The track at the bottom shows the amino acid sequence translated from codons at the 3′ end of *PPT1* exon 1. The horizontal dashed lines enclose the homozygous ***As*** at position +1 of intron 1 that destroy the canonical ***GT*** splice donor motif.](JVIM-31-149-g006){#jvim14632-fig-0006}

###### 

Palmitoyl protein thioesterase 1 exon 1 splice donor strength predictions

  Position of "G" in "GT" Motif   Motif              Maximum Entropy Score[a](#jvim14632-note-0006){ref-type="fn"}   Conclusion
  ------------------------------- ------------------ --------------------------------------------------------------- ------------------------
  c.124 + 1G (wild type)          tgg[GT]{.ul}GAGC   +7.23                                                           Potentially functional
  c.124 + 1G\>A (mutant)          tgg[AT]{.ul}GAGC   −0.95                                                           Not functional
  c.77G (exonic)                  ggc[GT]{.ul}CTGG   −10.70                                                          Not functional
  c.106G (exonic)                 ctg[GT]{.ul}GATC   +0.38                                                           Not functional
  c.124 + 19 (intronic)           ggg[GT]{.ul}CGGA   −3.58                                                           Not functional

Maximum Entropy Scores range from −20 (weakest) to +20 (strongest). Motifs with scores above +3 are predicted to be potentially functional donor splice sites.

John Wiley & Sons, Ltd

In 1995, *PPT1* became the first gene reported to harbor NCL‐causing mutations when 3 *PPT1* mutations were identified as probable causes for NCL in 42 infants, mostly from Finland.[14](#jvim14632-bib-0014){ref-type="ref"} Since then, at least 70 additional variant alleles in or around *PPT1* have been reported in human NCL patients (<http://www.ucl.ac.uk/ncl/CLN1mutationtable.htm>). *PPT1* encodes a soluble enzyme with palmitoyl protein thioesterase activity. The human disease caused by *PPT1* mutations is referred to as CLN1 (OMIM \#256730). Homozygous or compound heterozygous nullifying mutations in *PPT1* typically produce a severe form of NCL in which neurologic signs become apparent before or during the second year of life.[2](#jvim14632-bib-0002){ref-type="ref"} CLN1 patients seldom survive past their early teens. Hypomorphic *PPT1* mutations have been associated with less aggressive CLN1 disease in older children and adults. Currently, there are no medical treatments that can reverse or slow CLN1 disease progression.

At least 4 different transgenic mouse models carrying nullifying *Ppt1* mutations have been created and shown to exhibit CLN1‐like disease characteristics.[15](#jvim14632-bib-0015){ref-type="ref"}, [16](#jvim14632-bib-0016){ref-type="ref"}, [17](#jvim14632-bib-0017){ref-type="ref"}, [18](#jvim14632-bib-0018){ref-type="ref"} These models are the subjects of ongoing and planned evaluations of therapeutic interventions intended for human CLN1 patients.[19](#jvim14632-bib-0019){ref-type="ref"}, [20](#jvim14632-bib-0020){ref-type="ref"}, [21](#jvim14632-bib-0021){ref-type="ref"}, [22](#jvim14632-bib-0022){ref-type="ref"}, [23](#jvim14632-bib-0023){ref-type="ref"}, [24](#jvim14632-bib-0024){ref-type="ref"} Due to differences in longevity, size, and the complexities of neuroanatomy and behavior, canine NCL models have some advantages over rodent models for optimizing therapeutic interventions or establishing their efficacy. Indeed, a *TPP1*‐deficient canine model for the CLN2 form of NCL has been used to develop enzyme replacement treatment[25](#jvim14632-bib-0025){ref-type="ref"} and paved the way for ongoing human trials (<https://clinicaltrials.gov/ct2/show/NCT02678689>).

A previous report described a different homozygous canine *PPT1* mutation (*PPT1:c.736_737insC*) in a Dachshund with NCL.[26](#jvim14632-bib-0026){ref-type="ref"} The Dachshund *PPT1* frameshift mutation was predicted to encode a truncated gene product. Brain tissue from the affected Dachshund had only trace thioesterase activity, attributed to other thioesterases such as that encoded by *PPT2*.[26](#jvim14632-bib-0026){ref-type="ref"} In both the Dachshund CLN1 case and the currently described Cane Corso CLN1 case, the initial neurodegenerative changes became apparent when the dogs were approximately 8 months old. Both dogs were euthanized because of their increasingly severe neurologic signs. The Dachshund was euthanized at 14 months of age, whereas the Cane Corso was euthanized when only 10 months old. The earlier euthanasia of the much larger Cane Corso may have been influenced by difficulties caring for a large dog with deteriorating neurologic function. The NCL in both the Cane Corso and the *PPT1‐*deficient Dachshund had an early onset and rapid progression similar to that of *TPP1*‐deficient Dachshunds, but was earlier and more rapid than has been reported in dogs with other types of NCL (Table [3](#jvim14632-tbl-0003){ref-type="table-wrap"}). A similar association between the disease‐causing mutations and disease phenotype was recently confirmed by comparing the various types of human NCL.[27](#jvim14632-bib-0027){ref-type="ref"}

###### 

Ages at disease onset and euthanasia for dogs with genetically defined neuronal ceroid lipofuscinosis (NCL)

  Disease   Gene        Mutation           Breed                                  Age at Onset (Months)[a](#jvim14632-note-0005){ref-type="fn"}   Age at Euthanasia (Months)                       References
  --------- ----------- ------------------ -------------------------------------- --------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------
  CLN1      *PPT1*      *c.124 + 1G\>A*    Cane Corso                             8                                                               10                                               Current
  CLN1      *PPT1*      *c.736_737insC*    Dachshund                              8                                                               14                                               [25](#jvim14632-bib-0025){ref-type="ref"}
  CLN2      *CLN2*      *c.325delC*        Dachshund                              7--9                                                            12                                               [27](#jvim14632-bib-0027){ref-type="ref"}
  CLN5      *CLN5*      *c.619C\>T*        Border Collie, Australian Cattle Dog   12--23                                                          15--29                                           [6](#jvim14632-bib-0006){ref-type="ref"},[28](#jvim14632-bib-0028){ref-type="ref"},[29](#jvim14632-bib-0029){ref-type="ref"}
  CLN5      *CLN5*      *c.934_935delAG*   Golden Retriever                       13--17                                                          30--34                                           [2](#jvim14632-bib-0002){ref-type="ref"}
  CLN6      *CLN6*      *c.829T\>C*        Australian Shepherd                    18                                                              24                                               [30](#jvim14632-bib-0030){ref-type="ref"}
  CLN7      *MFSD8*     *c.843delT*        Chinese Crested Dog, Chihuahua         12                                                              16--24                                           [4](#jvim14632-bib-0004){ref-type="ref"},[5](#jvim14632-bib-0005){ref-type="ref"},[31](#jvim14632-bib-0031){ref-type="ref"}
  CLN8      *CLN8*      *c.491T\>C*        English Setter                         12--14                                                          24--27                                           [32](#jvim14632-bib-0032){ref-type="ref"},[33](#jvim14632-bib-0033){ref-type="ref"}
  CLN8      *CLN8*      *c.585G\>A*        Australian Shepherd                    11                                                              21                                               [3](#jvim14632-bib-0003){ref-type="ref"}
  CLN10     *CTSD*      *c.579G\>A*        American Bulldog                       11--36                                                          42--66[b](#jvim14632-note-0006){ref-type="fn"}   [34](#jvim14632-bib-0034){ref-type="ref"},[35](#jvim14632-bib-0035){ref-type="ref"}
  CLN12     *ATP13A2*   *c.1623G\>A*       Tibetan Terrier                        60--96                                                          Up to 120                                        [38](#jvim14632-bib-0038){ref-type="ref"},[39](#jvim14632-bib-0039){ref-type="ref"}

Almost all of the ages at onset were based on reports from owners not expecting their dogs to show abnormal signs. In a research setting, trained animal technicians can identify earlier onsets. For instance, research Dachshunds with CLN2 disease show abnormal signs by 5 months of age.

The late age at onset of American Bulldogs with CLN10 disease probably reflects residual cathepsin D enzymatic activity from a hypomorphic *CTSD:c.585A* allele.[35](#jvim14632-bib-0035){ref-type="ref"} Sheep, mice, and human babies with nullifying *CTSD* mutations have congenital NCL.[40](#jvim14632-bib-0040){ref-type="ref"}, [41](#jvim14632-bib-0041){ref-type="ref"}, [42](#jvim14632-bib-0042){ref-type="ref"}

John Wiley & Sons, Ltd

Tissues from the CLN1 affected Dachshund were examined by electron microscopy.[26](#jvim14632-bib-0026){ref-type="ref"} In that case, distinct membranes were observed to at least partially surround the storage material aggregates. As with the Cane Corso tissue, the initial fixation of the Dachshund tissue was in formalin; however, the partial preservation of the surrounding membranes in the case of the Dachshund was probably due to a shorter time interval between the initial fixation and the transfer to the glutaraldehyde fixative. Better ultrastructural preservation of the storage bodies in future cases will require initial fixation in glutaraldehyde at short postmortem times.

In conclusion, our findings indicate a novel splice donor mutation causing CLN1 in a dog breed previously unreported to possess the disease. A canine model for CLN1 disease could provide opportunities to further the development of therapeutic options, benefiting affected humans and dogs. Ancestors or littermates were not available for testing. To find a potential founder for a colony of *PPT1*‐deficient research dogs, all 5 Cane Corso DNA samples from our DNA repository and 26 Cane Corso DNA samples provided by MARS Veterinary™ were screened for the *PPT1c.124 + 1A* allele with a modified allelic discrimination assay that is described in the Data S1. All 31 Cane Corso DNA samples tested homozygous for the reference *PPT1c.124 + 1G* allele. In a continuing effort to identify dogs that could help develop effective treatments for infants with CLN1 disease and to assist breeders in avoiding the production of affected puppies, we are offering free DNA testing for Cane Corsos or Dachshunds showing visual deterioration and neurodegenerative changes starting around or before 8 months of age. Arrangements for free testing can be made with Martin Katz (<katzm@health.missouri.edu>).
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**Table S1.** Breeds and SRA numbers for the control whole genome sequences.

###### 

Click here for additional data file.
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